Compare prices and buy Emoxypine Succinate from 1 research peptide vendor - also called suppliers or sources. Updated daily.
The succinate salt of 2-ethyl-6-methyl-3-hydroxypyridine, marketed as Mexidol, a small-molecule drug rather than a peptide. Russian reviews attribute antioxidant and membrane-stabilizing activity to its hydroxypyridine part and support of mitochondrial energy metabolism to its succinate part, and report neuroprotective and antihypoxic effects. It is marketed as a medicine in Russia, where its manufacturer has run controlled trials in ischemic stroke and chronic cerebral ischemia, and it is not FDA-approved.
For research purposes only. Not medical advice.
Emoxypine succinate is not a peptide. It is a salt of 2-ethyl-6-methyl-3-hydroxypyridine, a substituted pyridine ring with no amino acids in it, paired one to one with succinic acid. PeptideScouter catalogues it under Nootropic & Neurological beside the Russian-developed nootropics such as Semax and Selank, a grouping by market rather than chemistry. Phenibut sits there on the same basis.
The CAS number on this row, 127464-43-1, belongs to the succinate salt, C12H17NO5, which PubChem lists at a molecular weight of 255.27. The free base, CAS 2364-75-2, is C8H11NO at 137.18, so it makes up about 54% of the salt's mass. A milligram figure stated for the succinate counts the whole salt unless a free-base amount is given, and it does not equal a milligram of another salt of the same base.
The controlled trials in ischemic stroke and chronic cerebral ischemia are sponsor-run. Three randomized, double-blind, placebo-controlled trials were sponsored by the manufacturer, Pharmasoft (RPC Pharmasoft LLC, Russia), and published in Russian in the Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. Each was entered on ClinicalTrials.gov only after it had finished, MEMO more than four years later.
EPICA (Stakhovskaya and colleagues, 2017) randomized 150 patients with hemispheric ischemic stroke at 11 Russian sites and followed them for 67 to 71 days. Its primary endpoint was the mean modified Rankin Scale (mRS) disability score at the final visit, where lower is better. The ClinicalTrials.gov results give 1.10 on the drug against 1.46 on placebo among the 124 patients who completed the study, a per-protocol analysis, and the paper reports the end-of-treatment difference at p=0.04.
MIR (Shamalov and colleagues, 2025) randomized 304 patients in the acute and early recovery periods of ischemic stroke in Russia, Uzbekistan and Kazakhstan. In the ClinicalTrials.gov results, which count the 279 patients who completed the study, the mean mRS score fell by 2.45 points on the drug and 2.01 on placebo by day 71. The paper compares median changes and reports that difference at p=0.003.
MEMO (Fedin and colleagues, 2021) randomized 318 patients with chronic cerebral ischemia at 15 centers in Russia and Uzbekistan. Montreal Cognitive Assessment (MoCA) scores, out of 30, rose by a mean 4.22 points on the drug against 2.17 on placebo at the end-of-treatment visit (day 75). That analysis covered the intention-to-treat population minus one participant with no data after randomization.
Every interventional study of the drug returned by a ClinicalTrials.gov search on October 22, 2026 names Pharmasoft as lead sponsor, including an open-label stroke study that began recruiting in Russia in November 2025.
In Russia, ethylmethylhydroxypyridine succinate is on the government's list of vital and essential medicines, in its group of other nervous-system drugs (Government Order No. 2406-r of October 12, 2019, as amended on January 15, 2025).
In the United States it has no approval and has not entered the compounding-list process that Semax and DSIP went through in 2026.
No. Emoxypine succinate is a small molecule, a one-to-one salt of 2-ethyl-6-methyl-3-hydroxypyridine with succinic acid, and contains no amino acids. The salt is C12H17NO5 at a molecular weight of 255.27, and the free base, C8H11NO at 137.18, makes up about 54% of that mass. PeptideScouter catalogues it with the Russian nootropic peptides because the two share a market, not a chemistry.
Two randomized, double-blind, placebo-controlled stroke trials sponsored by the manufacturer, Pharmasoft, and published in Russian measured disability on the modified Rankin Scale, where lower is better. In EPICA (2017, 150 patients randomized in Russia), the mean final score was 1.10 on the drug and 1.46 on placebo among the 124 patients who completed the study. In MIR (2025, 304 patients randomized in Russia, Uzbekistan and Kazakhstan), the mean score fell by 2.45 points on the drug and 2.01 on placebo among the 279 who completed it.
MEMO was a randomized, double-blind, placebo-controlled trial in 318 patients with chronic cerebral ischemia at 15 centers in Russia and Uzbekistan, sponsored by the manufacturer, Pharmasoft, and published in Russian in 2021. Montreal Cognitive Assessment scores, out of 30, rose by a mean 4.22 points on the drug and 2.17 on placebo at the end-of-treatment visit, in an intention-to-treat analysis that left out one participant with no follow-up data.
No. Drugs@FDA returned no application for emoxypine, its succinate salt or Mexidol as of October 22, 2026, and neither FDA's 503A nor its 503B bulk-substance nominations list names it. In Russia, ethylmethylhydroxypyridine succinate is on the government's list of vital and essential medicines.
They share one active base, 2-ethyl-6-methyl-3-hydroxypyridine, but not one form. Mexidol is the trade name of the succinate salt, molecular weight 255.27. Emoxypine, also spelled emoxipin, names the free base at 137.18, and FDA's substance registry files a separate hydrochloride salt at 173.64. Because the forms differ in weight, a milligram of one is not a milligram of another.
Emoxypine Succinate is sold by 1 research peptide vendor indexed on PeptideScouter, with 1 tracked listing compared per vendor in the table above. Pricing is normalized and refreshed daily.
All 1 indexed research peptide vendor currently have Emoxypine Succinate in stock. Stock state is refreshed daily from each vendor's catalog.
Discount codes are issued per vendor rather than per peptide, so any code applies across that vendor's whole catalog. All 1 vendor listing Emoxypine Succinate publish a PeptideScouter code, worth 10% off. These listings do not carry a comparable per-milligram price, so code availability is shown without a normalized effective price. Each vendor's code is shown beside its price in the table above.
1 research peptide vendor currently lists Emoxypine Succinate on PeptideScouter. We track 1 listing across size and kit variants.
Emoxypine Succinate's CAS Registry Number is 127464-43-1. It is also sold as Emoxypine, Mexidol, 2-Ethyl-6-methyl-3-hydroxypyridine Succinate.
